These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 39325128)

  • 1. The crossroad between tumor and endothelial cells.
    Ribatti D
    Clin Exp Med; 2024 Sep; 24(1):227. PubMed ID: 39325128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial Cells in the Tumor Microenvironment.
    Sobierajska K; Ciszewski WM; Sacewicz-Hofman I; Niewiarowska J
    Adv Exp Med Biol; 2020; 1234():71-86. PubMed ID: 32040856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors.
    Wachholz GE; Akbari P; Huijbers EJM; Jalan P; van Beijnum JR; Griffioen AW
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189155. PubMed ID: 39019408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumors resurrect an embryonic vascular program to escape immunity.
    Huijbers EJM; Khan KA; Kerbel RS; Griffioen AW
    Sci Immunol; 2022 Jan; 7(67):eabm6388. PubMed ID: 35030032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dark side of tumor-associated endothelial cells.
    De Sanctis F; Ugel S; Facciponte J; Facciabene A
    Semin Immunol; 2018 Feb; 35():35-47. PubMed ID: 29490888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular vimentin as a versatile immune suppressive protein in cancer.
    van Loon K; van Breest Smallenburg ME; Huijbers EJM; Griffioen AW; van Beijnum JR
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188985. PubMed ID: 37717859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.
    Nowak-Sliwinska P; van Beijnum JR; Griffioen CJ; Huinen ZR; Sopesens NG; Schulz R; Jenkins SV; Dings RPM; Groenendijk FH; Huijbers EJM; Thijssen VLJL; Jonasch E; Vyth-Dreese FA; Jordanova ES; Bex A; Bernards R; de Gruijl TD; Griffioen AW
    Angiogenesis; 2023 May; 26(2):279-293. PubMed ID: 36459240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular galectins in tumor angiogenesis and cancer immunity.
    Thijssen VLJL
    Semin Immunopathol; 2024 Jul; 46(1-2):3. PubMed ID: 38990363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial Progenitors in the Tumor Microenvironment.
    Testa U; Pelosi E; Castelli G
    Adv Exp Med Biol; 2020; 1263():85-115. PubMed ID: 32588325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of endothelial cells in tumor microenvironment.
    Yang D; Guo P; He T; Powell CA
    Clin Transl Med; 2021 Jun; 11(6):e450. PubMed ID: 34185401
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
    Dirkx AE; oude Egbrink MG; Castermans K; van der Schaft DW; Thijssen VL; Dings RP; Kwee L; Mayo KH; Wagstaff J; Bouma-ter Steege JC; Griffioen AW
    FASEB J; 2006 Apr; 20(6):621-30. PubMed ID: 16581970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis.
    Chandler KB; Costello CE; Rahimi N
    Cells; 2019 Jun; 8(6):. PubMed ID: 31195728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
    Tzeng HT; Huang YJ
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
    Albini A; Bruno A; Noonan DM; Mortara L
    Front Immunol; 2018; 9():527. PubMed ID: 29675018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between cancer cells and endothelial cells: implications for tumor progression and intervention.
    Choi H; Moon A
    Arch Pharm Res; 2018 Jul; 41(7):711-724. PubMed ID: 29961196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-3 is a novel target to interfere with tumor vasculature.
    Dentelli P; Rosso A; Olgasi C; Camussi G; Brizzi MF
    Oncogene; 2011 Dec; 30(50):4930-40. PubMed ID: 21643009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galectins: Multitask signaling molecules linking fibroblast, endothelial and immune cell programs in the tumor microenvironment.
    Elola MT; Ferragut F; Méndez-Huergo SP; Croci DO; Bracalente C; Rabinovich GA
    Cell Immunol; 2018 Nov; 333():34-45. PubMed ID: 29602445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response.
    Matejuk A; Collet G; Nadim M; Grillon C; Kieda C
    Arch Immunol Ther Exp (Warsz); 2013 Aug; 61(4):285-99. PubMed ID: 23575964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.